JPH0327555B2 - - Google Patents
Info
- Publication number
- JPH0327555B2 JPH0327555B2 JP61036988A JP3698886A JPH0327555B2 JP H0327555 B2 JPH0327555 B2 JP H0327555B2 JP 61036988 A JP61036988 A JP 61036988A JP 3698886 A JP3698886 A JP 3698886A JP H0327555 B2 JPH0327555 B2 JP H0327555B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- reaction
- membranes
- fluorine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 phosphate ester Chemical class 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 229910019142 PO4 Inorganic materials 0.000 claims description 13
- 239000010452 phosphate Substances 0.000 claims description 13
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 150000003839 salts Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 150000003973 alkyl amines Chemical class 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 25
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 17
- 239000012528 membrane Substances 0.000 description 12
- 235000011007 phosphoric acid Nutrition 0.000 description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 9
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 9
- 238000001338 self-assembly Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 4
- 239000003012 bilayer membrane Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229920005597 polymer membrane Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 150000003014 phosphoric acid esters Chemical class 0.000 description 3
- 230000000865 phosphorylative effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UPSJKWVICNHZIJ-UHFFFAOYSA-M sodium;1,1,2,2,3,3,4,4,5,5,6,6,7,7,10,10,10-heptadecafluorodecyl [2-hydroxy-3-(2-methylprop-2-enoyloxy)propyl] phosphate Chemical compound [Na+].CC(=C)C(=O)OCC(O)COP([O-])(=O)OC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)CCC(F)(F)F UPSJKWVICNHZIJ-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KOWOGKUTCSIJFZ-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6,7,7,10,10,10-heptadecafluorodecyl dihydrogen phosphate Chemical compound OP(O)(=O)OC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)CCC(F)(F)F KOWOGKUTCSIJFZ-UHFFFAOYSA-N 0.000 description 1
- LZHCVNIARUXHAL-UHFFFAOYSA-N 2-tert-butyl-4-ethylphenol Chemical compound CCC1=CC=C(O)C(C(C)(C)C)=C1 LZHCVNIARUXHAL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- DHCGNXDXGPMUER-UHFFFAOYSA-N [1,1,2,3,3,4,4,5,5,6,10,10,10-tridecafluoro-2-(1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexyl)decyl] dihydrogen phosphate Chemical compound C(CC(C(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(C(OP(=O)(O)O)(F)F)F)(F)F)(F)F)(F)F)F)CC(F)(F)F DHCGNXDXGPMUER-UHFFFAOYSA-N 0.000 description 1
- WKUISSZJLAODLR-UHFFFAOYSA-N [3-[1,1,2,2,3,3,4,4,5,5,6,6,7,7,10,10,10-heptadecafluorodecoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)COP(O)(=O)OC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)CCC(F)(F)F WKUISSZJLAODLR-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Description
〔産業上の利用分野〕
本発明は、新規なリン酸エステル、更に詳しく
は界面活性、自己組織性及び重合性を有する含フ
ツ素リン酸エステルに関する。
〔従来の技術及び発明が解決しようとする問題
点〕
細胞は生命体の最小単位であり、細胞膜により
覆われている。この細胞膜は、細胞の仕切りと区
画形成、細胞運動、物質輸送、情報伝達等の様々
な機能を有しており、生命活動の源となつてい
る。
一方、高分子化学の分野において、これら細胞
膜の持つている機能を有する人口高分子膜を造
り、広く工学、医学、薬学等の幅広い分野へ応用
を図ろうとする研究が近年盛んに行われてきてい
る。
例えば、物質輸送機能を備えた高分子分離膜の
研究が行われており、人工高分子膜は、工学の分
野においてイオン交換膜、透析膜、限外ろ過膜、
逆浸透膜、ガス分離膜等広く工業的に用いられて
いる。また、医学の分野においても人工腎蔵にみ
られる溶質透過性の血液浄化用の膜、人工心肺に
みられる気体透過性の血液浄化用の膜等の研究が
盛んに行われている。
また、区画保護機能を備えたマイクロカプセル
の研究が行われ、人工高分子膜は液体、例えば香
料のマイクロカプセル化やインクをマイクロカプ
セル化した複写紙に応用されている。さらに、透
過機能を兼ねそなえたマイクロカプセルの応用と
して医薬の徐放性製剤システムや酵素のマイクロ
カプセル化、人工赤血球等の研究が行われてい
る。
更にまた、細胞膜がリン脂質の二分子構膜造で
あることが明らかになり、細胞膜と同じような二
分子膜ベシクル(リポソーム)を天然のリン脂質
を用いて造り(天然リポソーム)、生体膜のモデ
ル物質として生体膜の種々の現象の解明に利用さ
れている。生体膜は、リン脂質分子の持つ物理的
性質、いわゆる疎水性と親水性を持つ両親媒性化
合物特有の自ら集合し組織化する性質(自己組織
性)により秩序よく配向し、二分子膜構造を形成
している。従つて、従来の人工高分子膜は生体膜
とは全く構造の異なるものであつた。
ところが、近年、天然リン脂質のみならず合成
化合物でも自己組織性を有し二分子膜構造を形成
しうる化合物が種々見出され、合成化合物を用い
て人工リポソームが造れるようになつた。さらに
は、この二分子膜構造を高分子化して膜の安定化
を図つた高分子リポソームの研究も盛んになつて
きており、モノマーとして使用される疎水基ある
いは親水基に重合性基を持つ化合物、例えばレー
ガン(Regan)らにより下式()で示される化
合物が合成されている〔ジヤーナル・オブ・ジ・
アメリカン・ケミカル・ソサイエテイー(J.
Amer.Chem.Soc.)、105、2975(1983)〕。
このようにして得られる天然、人工、及び高分
子リポソームという形態は一種のマイクロカプセ
ルとも考えられ、将来、工学、医学等への応用展
開が期待されているものである。従つて、膜に用
いる材としてのモノマーを考えた場合、そのモノ
マーの持つている化学的性質ばかりでなく界面活
性能、自己組織能等の物理的性質を有し、かつ将
来の医薬や医用高分子等への応用を考えた場合、
生体との適合性の良い物質が望まれる。リン脂質
は、まさにこれら界面活性、自己組織性、生体親
和性等の望ましい機能を有しており、リン脂質に
重合性基を導入した化合物は益々注目されてい
る。
〔発明が解決しようとする問題点〕
しかしながら、リン脂質は高純度のものが入手
し難いこと、高価であること等から、その応用に
も限界があり、工業的に容易に製造することがで
き、界面活性、自己組織性、及び重合性を有し、
かつ人体に対する安全性の高いリン酸エステル系
モノマーの開発が望まれていた。
〔問題点を解決するための手段〕
斯かる実情において、本発明者は鋭意研究を行
ない、次の一般式()
(式中、R′は水素原子またはメチル基、Rは炭
素数1〜36の直鎖もしくは分岐鎖のアルキル基、
Mは水素原子、アルカリ金属、アンモニウムまた
はアルキルアミンもしくはアルカノールアミンの
塩であることを示す)
で表わされるリン酸エステルが界面活性能、自己
組織能及び重合性を有することを見い出し、先に
特許出願した(特願昭60−57025号)。
本発明者はさらに研究を行なつたところ、前記
式()中Rに含フツ素アルキル基を導入した新
規な含フツ素リン酸エステルが優れた界面活性
能、自己組織能及び重合性を有し、しかも安価か
つ容易に入手可能な原料から簡単な操作で高純度
かつ高収率で合成することができることを見出
し、本発明を完成した。
すなわち本発明は次の一般式()
(式中のR′は水素原子またはメチル基、Rfは炭
素数1〜36の直鎖もしくは分岐鎖の、少なくとも
一つ以上の水素原子がフツ素原子で置換されたフ
ルオロアルキル基、Mは水素原子またはアルカリ
金属、アンモニウム、アルキルアミンもしくはア
ルカノールアミンの塩であることを示す。)
で表される含フツ素リン酸エステルを提供するも
のである。
本発明の式()で示される含フツ素リン残エ
ステルは、例えば次の反応式に従い、式()で
表されるモノ フルオロアルキルリン酸のモノア
ルカリ金属塩に式()で示されるメタクリル酸
グリシジル、もしくはアクリル酸グリシジルを反
応させ含フツ素リン酸エステル(Ia)を製造し、
必要により酸性化、更に塩基により中和すること
により容易に製造できる。
(式中、M′はアルカリ金属を示し、Rf、R′は前
記と同じ。)
式()で表される含フツ素リン酸エステルに
おいて、Rfで表される炭素数1〜36の直鎖もし
くは分岐鎖の、少なくとも一つ以上の水素原子が
フツ素原子で置換されたフルオロアルキル基とし
てはトリデカフルオロオクチル、ヘプタデカフル
オロドデシル、ヘンエイコサフルオロドデシル、
ペンタコサフルオロテトラデシル、ノナコサフル
オロヘキサデシル、トリトリアコンタフルオロオ
クタデシル、2−ペンタフルオロエチルペンタフ
ルオロヘキシル、2−トリデカフルオロヘキシル
トリデカフルオロデシル、2−ヘプタデカフルオ
ロオクチルヘプタデカフルオロドデシル、2−ヘ
ンエイコサフルオロデシルヘンエイコサフルオロ
テトラデシル、2−ペンタコサフルオロドデシル
ペンタコサフルオロヘキサデシル、2−ノナコサ
フルオロテトラデシルノナコサフルオロオクタデ
シル基等が挙げられるが、就中、界面活性能、自
己組織能の点で炭素数8〜36のものが好ましい。
特に好ましい例としては、トリデカフルオロオク
チル、ヘプタデカフルオロデシル、ヘンエイコサ
フルオロドデシル、2−トリデカフルオロヘキシ
ルトリデカフルオロデシル基が挙げられる。
R′で表わされる基としてはメチル基が好まし
い。
上記反応式中、式()で表されるモノ フル
オロアルキルリン酸塩は、対応する含フツ素アル
キル基を有する有機ヒドロキシ化合物に五酸化リ
ン、オキシ塩化リン、ポリリン酸等のリン酸化剤
を反応させモノ フルオロアルキルリン酸を得た
のち中和することにより得ることができ、そのい
ずれの方法で得られたものでもよいが、本発明の
含フツ素リン酸エステル()の製造に使用され
るモノ フルオロアルキルリン酸塩()は高純
度であるのが好ましい。モノ フルオロアルキル
リン酸塩の純度が低く、副生された不純物が多く
混入していると次のような幣害を生じる。すなわ
ち、五酸化リンやオキシ塩化リンをリン酸化剤と
して用いた時に副生するジ フルオロアルキルリ
ン酸塩が含まれるとモノ フルオロアルキルリン
酸としての界面活性能、自己組織能が低下、もし
くはなくなり、さらに次のエポキシ化合物との反
応において目的化合物の純度を低下させるととも
に、高純度の目的化合物を得るための精製が困難
になる。また、ポリリン酸をリン酸化剤として用
いた時に副生するオルトリン酸もエポキシ化合物
との反応において目的の反応の収率を低下させ、
さらに目的化合物の純度を低下させるとともに、
高純度の目的化合物を得るための精製が困難とな
る。従つて、モノ フルオロアルキルリン酸塩
()としては、90重量%以上の純度のものを使
うことが好ましい。
上記反応において、メタクリル酸グリシジルも
しくはアクリル酸グリシジル()は、モノ フ
ルオロアルキルリン酸のモノアルカリ金属塩
()1モルに対し1〜10モル、特に、3〜5モ
ル反応させるのが好ましい。
モノ フルオロアルキルリン酸をモノアルカリ
金属塩にすることなく本反応を行うと目的の化合
物ばかりでなく、さらにもう1モルの式()で
示される化合物が反応したリン酸トリエステルが
副生し、また、反応終了時において、系が酸性で
あるためにエステル結合が加水分解をうけやすく
なり目的化合物の収率を低下させ、好ましくな
い。従つて、本反応を実施するに際しはモノ フ
ルオロアルキルリン酸はモノアルカリ金属塩の形
で使用することが必要である。
反応に用いる溶媒は不活性の極性溶媒、例えば
水、メチルアルコール、エチルアルコール等が用
いられるが、就中水が好ましい。
反応温度としては30〜100℃、特に50〜90℃で
反応を行うのが好ましい。
さらに、反応時において重合禁止、もしくは重
合抑制剤を添加しても良く、例えばハイドロキノ
ンモノメチルエーテル、ハイドロキノン、2,
2′−メチレンビス(4−エチル−6−t−ブチル
フエノール)等を(メタ)アクリル酸グリシジル
に対して50〜10000ppmを加えるのが好ましい。
かくして得られた反応液中には目的化合物であ
る含フツ素リン酸エステル()の他に未反応の
式()で示される化合物、あるいは式()で
示される化合物のエポキシ部分が加水分解された
グリセリルメタクリレートが含まれている。使用
目的によつては反応生成物をそのまま用いること
も可能であるが、このものを更に精製して高純度
品を得ることができる。例えば、ヘプタデカフル
オロデシル 2−ヒドロキシ−3−メタクリロイ
ロキシプロピルリン酸ナトリウム〔式()の化
合物においてR′=CH3、Rf=C2H4C8F17、M=
Na、以下、化合物()と称する〕の場合には
ヘプタデカフルオロデシルリン酸ナトリウムの水
溶液にメタクリル酸グリシジルを反応させた後、
反応液にアセトンを加え冷却することにより、生
成したヘプタデカフルオロデシル 2−ヒドロキ
シ−3−メタクリロイロキシプロピルリン酸ナト
リウムを析出させて、アセトンに可溶なメタクリ
ル酸グリシジルの加水分解物と分離し純度のよい
目的物を得ることができる。酸型のヘプタデカフ
ルオロデシル 2−ヒドロキシ−3−メタクリロ
イロキシプロピルリン酸〔式()の化合物にお
いてR′=CH3、Rf=C2H4C8F17、M=H〕につい
ては上記のようにして得られたNa塩の水溶液を
酸、例えば塩酸等で酸性にし、エチルエーテル等
の溶剤で抽出することにより得ることができる。
尚、本発明において、反応条件によつては下式
()で示される化合物が少量生成することがあ
る。
(式中のRf、R′、Mは、前記と同じ。)
〔作用〕
本発明化合物()が優れた界面活性剤を示す
ことは、その水溶液の表面張力が低下することか
らわかる。表1に示す如く、特に、本発明者が先
に特許出願した一般式()の化合物よりも優れ
ている。
[Industrial Application Field] The present invention relates to a novel phosphoric acid ester, and more particularly to a fluorine-containing phosphoric acid ester having surface activity, self-assembly properties, and polymerizability. [Problems to be solved by the prior art and the invention] A cell is the smallest unit of a living organism, and is covered by a cell membrane. This cell membrane has various functions such as cell partition and compartment formation, cell movement, substance transport, and information transmission, and is the source of life activities. On the other hand, in the field of polymer chemistry, research has been actively conducted in recent years to create artificial polymer membranes that have the functions possessed by cell membranes and to apply them to a wide range of fields such as engineering, medicine, and pharmacy. There is. For example, research is being conducted on polymer separation membranes with mass transport functions, and artificial polymer membranes are widely used in the engineering field as ion exchange membranes, dialysis membranes, ultrafiltration membranes,
Widely used industrially, such as reverse osmosis membranes and gas separation membranes. In addition, in the field of medicine, research is actively being conducted on solute-permeable blood purification membranes found in artificial kidneys and gas-permeable blood purification membranes found in heart-lung machines. Research has also been conducted on microcapsules with a compartmental protection function, and artificial polymer membranes have been applied to microencapsulation of liquids, such as fragrances, and copy paper with microencapsulation of ink. Furthermore, research is being conducted on applications of microcapsules that also have a permeability function, such as sustained release drug formulation systems, microencapsulation of enzymes, and artificial red blood cells. Furthermore, it has become clear that the cell membrane is a bimolecular structure of phospholipids, and bilayer membrane vesicles (liposomes) similar to cell membranes are made using natural phospholipids (natural liposomes). It is used as a model material to elucidate various phenomena in biological membranes. Biological membranes are oriented in an orderly manner due to the physical properties of phospholipid molecules, which are unique to amphiphilic compounds with hydrophobic and hydrophilic properties (self-organization), and form a bilayer membrane structure. is forming. Therefore, conventional artificial polymer membranes have a completely different structure from biological membranes. However, in recent years, not only natural phospholipids but also synthetic compounds have been discovered that have self-assembly properties and can form bilayer membrane structures, and it has become possible to create artificial liposomes using synthetic compounds. Furthermore, research into polymer liposomes, which stabilize the membrane by polymerizing this bilayer membrane structure, has become active, and compounds with polymerizable groups in the hydrophobic or hydrophilic groups used as monomers are being actively researched. For example, a compound represented by the following formula () has been synthesized by Regan et al.
American Chemical Society (J.
Amer.Chem.Soc.), 105 , 2975 (1983)]. The forms of natural, artificial, and polymeric liposomes obtained in this way can be considered as a type of microcapsule, and are expected to be applied in engineering, medicine, etc. in the future. Therefore, when considering the monomer used as a material for membranes, it is important to note that the monomer has not only chemical properties but also physical properties such as surfactant ability and self-organizing ability, and that it is suitable for future pharmaceuticals and medical applications. When considering application to molecules, etc.
A substance with good compatibility with living organisms is desired. Phospholipids have exactly these desirable functions such as surface activity, self-assembly, and biocompatibility, and compounds in which polymerizable groups are introduced into phospholipids are attracting increasing attention. [Problems to be solved by the invention] However, phospholipids are difficult to obtain with high purity and are expensive, so there are limits to their application, and they cannot be easily produced industrially. , has surface activity, self-assembly property, and polymerizability,
It has been desired to develop a phosphate ester monomer that is also highly safe for the human body. [Means for Solving the Problems] Under these circumstances, the inventor has conducted extensive research and has developed the following general formula (). (In the formula, R' is a hydrogen atom or a methyl group, R is a straight or branched alkyl group having 1 to 36 carbon atoms,
M represents a hydrogen atom, an alkali metal, ammonium, or a salt of an alkylamine or an alkanolamine). (Special Application No. 60-57025). The present inventor conducted further research and found that a novel fluorine-containing phosphoric acid ester in which a fluorine-containing alkyl group was introduced into R in the above formula () has excellent surfactant ability, self-assembly ability, and polymerizability. However, they have discovered that it can be synthesized with high purity and high yield by simple operations from inexpensive and easily available raw materials, and have completed the present invention. That is, the present invention is based on the following general formula () (R' in the formula is a hydrogen atom or a methyl group, Rf is a linear or branched fluoroalkyl group having 1 to 36 carbon atoms in which at least one hydrogen atom is substituted with a fluorine atom, M is hydrogen (indicates that it is a salt of an alkali metal, ammonium, alkylamine or alkanolamine). The fluorine-containing phosphorus residual ester represented by the formula () of the present invention can be obtained by adding methacrylic acid represented by the formula () to a monoalkali metal salt of a monofluoroalkyl phosphoric acid represented by the formula (), for example, according to the following reaction formula. A fluorine-containing phosphate ester (Ia) is produced by reacting glycidyl or glycidyl acrylate,
It can be easily produced by acidification if necessary and further neutralization with a base. (In the formula, M' represents an alkali metal, and Rf and R' are the same as above.) In the fluorine-containing phosphate ester represented by the formula (), a linear chain having 1 to 36 carbon atoms represented by Rf Or as a branched fluoroalkyl group in which at least one hydrogen atom is substituted with a fluorine atom, tridecafluorooctyl, heptadecafluorododecyl, heneicosafluorododecyl,
Pentacosafluorotetradecyl, nonacosafluorohexadecyl, tritriacontafluorooctadecyl, 2-pentafluoroethylpentafluorohexyl, 2-tridecafluorohexyltridecafluorodecyl, 2-heptadecafluorooctylheptadecafluorododecyl, 2 -heneicosafluorodecylheneicosafluorotetradecyl, 2-pentacosafluorododecylpentacosafluorohexadecyl, 2-nonacosafluorotetradecylnonacosafluorooctadecyl group, among others, surfactant ability, Those having 8 to 36 carbon atoms are preferred from the viewpoint of self-assembly ability.
Particularly preferred examples include tridecafluorooctyl, heptadecafluorodecyl, heneicosafluorododecyl, and 2-tridecafluorohexyltridecafluorodecyl groups. The group represented by R' is preferably a methyl group. In the above reaction formula, the monofluoroalkyl phosphate represented by the formula () is produced by reacting a phosphorylating agent such as phosphorus pentoxide, phosphorus oxychloride, or polyphosphoric acid with the corresponding organic hydroxy compound having a fluorine-containing alkyl group. It can be obtained by obtaining monofluoroalkyl phosphoric acid and then neutralizing it, and it may be obtained by any of these methods, but it can be used in the production of the fluorine-containing phosphate ester () of the present invention. Preferably, the monofluoroalkyl phosphate () is of high purity. If the purity of the monofluoroalkyl phosphate is low and it is contaminated with many by-product impurities, the following damage will occur. In other words, when phosphorus pentoxide or phosphorus oxychloride is used as a phosphorylating agent, if difluoroalkyl phosphate is a by-product, the surfactant ability and self-assembly ability of monofluoroalkyl phosphate will decrease or disappear. Furthermore, in the subsequent reaction with an epoxy compound, the purity of the target compound is reduced, and purification to obtain a highly pure target compound becomes difficult. In addition, orthophosphoric acid, which is produced as a by-product when polyphosphoric acid is used as a phosphorylating agent, also reduces the yield of the desired reaction in the reaction with the epoxy compound.
In addition to reducing the purity of the target compound,
Purification to obtain a highly pure target compound becomes difficult. Therefore, it is preferable to use a monofluoroalkyl phosphate () with a purity of 90% by weight or more. In the above reaction, glycidyl methacrylate or glycidyl acrylate () is preferably reacted in an amount of 1 to 10 moles, particularly 3 to 5 moles, per mole of the monoalkali metal salt of monofluoroalkyl phosphoric acid (). If this reaction is carried out without converting the monofluoroalkyl phosphoric acid into a monoalkali metal salt, not only the desired compound but also phosphoric acid triester in which 1 mole of the compound represented by the formula () has reacted will be produced as a by-product. Moreover, at the end of the reaction, since the system is acidic, the ester bonds are susceptible to hydrolysis, which reduces the yield of the target compound, which is undesirable. Therefore, when carrying out this reaction, it is necessary to use monofluoroalkyl phosphoric acid in the form of a monoalkali metal salt. The solvent used in the reaction is an inert polar solvent such as water, methyl alcohol, ethyl alcohol, etc., and water is particularly preferred. The reaction temperature is preferably 30 to 100°C, particularly 50 to 90°C. Furthermore, polymerization inhibitors or polymerization inhibitors may be added during the reaction, such as hydroquinone monomethyl ether, hydroquinone, 2,
It is preferable to add 2'-methylenebis(4-ethyl-6-t-butylphenol) or the like in an amount of 50 to 10,000 ppm based on glycidyl (meth)acrylate. In the reaction solution thus obtained, in addition to the target compound, the fluorine-containing phosphate ester (), the unreacted compound represented by the formula () or the epoxy moiety of the compound represented by the formula () is hydrolyzed. Contains glyceryl methacrylate. Depending on the purpose of use, the reaction product may be used as it is, but it may be further purified to obtain a highly pure product. For example, sodium heptadecafluorodecyl 2 - hydroxy-3 - methacryloyloxypropyl phosphate [in the compound of formula (), R'= CH3 , Rf= C2H4C8F17 , M =
In the case of Na, hereinafter referred to as compound ()], after reacting glycidyl methacrylate with an aqueous solution of sodium heptadecafluorodecyl phosphate,
By adding acetone to the reaction solution and cooling it, the produced sodium heptadecafluorodecyl 2-hydroxy-3-methacryloyloxypropyl phosphate was precipitated and separated from the acetone-soluble glycidyl methacrylate hydrolyzate. A target product with good purity can be obtained. Regarding the acid form of heptadecafluorodecyl 2-hydroxy-3-methacryloyloxypropyl phosphate [R'=CH 3 , Rf=C 2 H 4 C 8 F 17 , M=H in the compound of formula ()], see above. It can be obtained by making the aqueous solution of Na salt obtained in the above manner acidic with an acid such as hydrochloric acid and extracting with a solvent such as ethyl ether. In the present invention, a small amount of the compound represented by the following formula () may be produced depending on the reaction conditions. (Rf, R' and M in the formula are the same as above.) [Function] The fact that the compound () of the present invention is an excellent surfactant can be seen from the fact that the surface tension of its aqueous solution decreases. As shown in Table 1, it is particularly superior to the compound of general formula () for which the present inventor previously applied for a patent.
本発明の含フツ素リン酸エステルは、界面活性
能、自己組織能及び重合性を有し、かつ、人体に
対する安全性が高く、しかも工業的に極めて有利
に製造しうるものである。従つて、工学、医学等
の分野において幅広く利用しうるものである。
〔実施例〕
次に実施例を挙げて本発明を説明する。
実施例 1
反応器に純度97%のヘプタデカフルオロデシル
リン酸95.5g(0.19モル、ただしこの試料のAV1
(本リン酸モノエステルの試料1gを第一当量点
まで中和するのに必要なKOHのmg数、以下も同
様)=108.9、AV2=(本リン酸モノエステルの試
料1gを第二当量点まで中和するのに必要な
KOHのmg数、以下も同様)=217.0であつた)を
投入し、1規定水酸化ナトリウム水溶液185mlを
加えて撹拌し、70℃に昇温して均一にした。この
時反応系の醸価(試料1gを中和するのに必要な
KOHのmgの数、以下も同様)は36.8であつた。
次に反応系を70℃に保ちながら、メタクリル酸グ
リシジル104.5g(0.74モル)を徐々に加え、こ
の温度で9時間撹拌し、この時の反応系の酸価は
ほぼ0になり、反応が完結したことが分かる。ま
た、この時の試料を、HPLC(高速液体クロマト
グラフイー、以下も同様)で分析したところ未反
応のメタクリル酸グリシジルのピークが認められ
た。さらに撹拌を続け合計20時間反応したところ
でメタクリル酸グリシジルは完全に加水分解され
てなくなつており、メタクリル酸グリシジルのエ
ポキシ部が加水分解されたメタクリル酸グリセリ
ルと目的化合物のピークが認められた。次に反応
液を室温まで冷やし、アセトン200gを加え、−5
℃に冷却するとヘプタデカフルオロデシル 2−
ヒドロキシ−3−メタクリロイロキシプロピルリ
ン酸ナトリウムが92g(収率70%)得られた。
1H NMR:
δ2.0ppm(s、3H、H2=C−CH3 )
δ2.6ppm(tt、2H、−P−OCH2CH2 F2−)
δ3.5〜4.5ppm(m、7H、
The fluorine-containing phosphate ester of the present invention has surfactant ability, self-assembly ability, and polymerizability, is highly safe for the human body, and can be produced industrially with great advantage. Therefore, it can be widely used in fields such as engineering and medicine. [Example] Next, the present invention will be explained with reference to Examples. Example 1 95.5 g of 97% pure heptadecafluorodecyl phosphoric acid (0.19 mol, but the AV1 of this sample
(Number of mg of KOH required to neutralize 1 g of sample of this phosphoric acid monoester to the first equivalent point, the same applies below) = 108.9, AV2 = (Number of mg of KOH required to neutralize 1 g of sample of this phosphoric acid monoester to the second equivalent point) necessary to neutralize up to
The number of mg of KOH (the same applies hereafter) was 217.0), and 185 ml of a 1N aqueous sodium hydroxide solution was added and stirred, and the temperature was raised to 70°C to make it homogeneous. At this time, the brewing value of the reaction system (necessary to neutralize 1 g of sample)
The number of mg of KOH (hereinafter the same) was 36.8.
Next, while keeping the reaction system at 70°C, 104.5 g (0.74 mol) of glycidyl methacrylate was gradually added and stirred at this temperature for 9 hours. At this time, the acid value of the reaction system became almost 0, and the reaction was completed. I know what you did. Furthermore, when the sample at this time was analyzed by HPLC (high performance liquid chromatography, the same applies hereinafter), a peak of unreacted glycidyl methacrylate was observed. After further stirring and reaction for a total of 20 hours, glycidyl methacrylate was completely hydrolyzed and disappeared, and peaks of glyceryl methacrylate and the target compound, in which the epoxy moiety of glycidyl methacrylate was hydrolyzed, were observed. Next, cool the reaction solution to room temperature, add 200 g of acetone, and -5
When cooled to ℃, heptadecafluorodecyl 2-
92 g (yield 70%) of sodium hydroxy-3-methacryloyloxypropyl phosphate was obtained. 1 H NMR : δ2.0ppm (s, 3H , H2 = C- CH3 ) δ2.6ppm (tt, 2H, -P -OCH2CH2F2-) δ3.5-4.5ppm (m, 7H,
【式】) δ5.6ppm(broad s、1H、【formula】) δ5.6ppm (broad s, 1H,
【式】) δ6.1ppm(broad s、1H、【formula】) δ6.1ppm (broad s, 1H,
【式】)
13C NMR(標準試料:Si(CH3)4)
元素分析
δ(ppm):a18.5、i33.4、h58.7、e66.5、g67.6、
f69.9、b126.5、c137.6、d168.9[Formula]) 13 C NMR (Standard sample: Si(CH 3 ) 4 ) Elemental analysis δ (ppm): a18.5, i33.4, h58.7, e66.5, g67.6,
f69.9, b126.5, c137.6, d168.9
【表】
HPLCで分析した結果、純度は98〜99%であつ
た。
試験例 1
実施例1で得たヘプタデカフルオロデシル 2
−ヒドロキシ−3−メタクリロイロキシプロピル
リン酸ナトリウム〔化合物()〕の約10%水溶
液に重合開始剤としてK2S2O8を対化合物()
1%加え、60〜70℃で4〜5時間加熱すると、無
色透明の高粘度水溶液が作られ、さらに、この重
合物をスライドグラス上にのせ放置すると無色透
明の膜状物質がえられた。
また、この高粘度水溶液は非等方性の性質があ
り、組織的な液晶構造を有していた。
実施例 2
純度92%の2−トリデカフルオロヘキシルトリ
デカフルオロデシルリン酸20g(0.025モル、た
だしこの試料のAV1=70.1、AV2=139.8)を1
規定水酸化ナトリウム水溶液24.8ml中に分散し
(この時の反応系の酸価は31.1であつた)、70℃で
メタクリル酸グリシジル14.2g(0.10モル)を
徐々に加え、この温度で30時間撹拌した。この時
の反応系の酸価は、ほぼ0でモノアルキルリン酸
の反応率は100%であることがわかる。反応液を
HPLCで分析したところ、メタクリル酸グリシジ
ルの加水分解物と新たな生成物のピークが見られ
た。これから生成物をHPLCで分取し、溶媒を減
圧留去すると、2−トリデカフルオロヘキシルト
リデカフルオロデシル 2−ヒドロキシ−3−メ
タクリロイロキシプロピルリン酸ナトリウムが
21.5g(収率89%)得られた。
元素分析[Table] As a result of HPLC analysis, the purity was 98-99%. Test Example 1 Heptadecafluorodecyl obtained in Example 1 2
- Add K 2 S 2 O 8 as a polymerization initiator to an approximately 10% aqueous solution of sodium hydroxy-3-methacryloyloxypropyl phosphate [compound ()] as a counter compound ()
When 1% of the polymer was added and heated at 60 to 70°C for 4 to 5 hours, a colorless and transparent high viscosity aqueous solution was produced.Furthermore, when this polymer was placed on a slide glass and left to stand, a colorless and transparent film-like substance was obtained. Moreover, this high viscosity aqueous solution had anisotropic properties and had an organized liquid crystal structure. Example 2 20 g of 2-tridecafluorohexyltridecafluorodecyl phosphoric acid (0.025 mol, however, AV1 = 70.1, AV2 = 139.8 of this sample) with a purity of 92% was added to 1
Disperse in 24.8 ml of normal sodium hydroxide aqueous solution (the acid value of the reaction system at this time was 31.1), gradually add 14.2 g (0.10 mol) of glycidyl methacrylate at 70°C, and stir at this temperature for 30 hours. did. It can be seen that the acid value of the reaction system at this time was approximately 0, and the reaction rate of monoalkyl phosphoric acid was 100%. reaction solution
When analyzed by HPLC, peaks of a hydrolyzate of glycidyl methacrylate and a new product were observed. The product was separated by HPLC and the solvent was distilled off under reduced pressure to obtain 2-tridecafluorohexyltridecafluorodecyl 2-hydroxy-3-methacryloyloxypropyl sodium phosphate.
21.5g (yield 89%) was obtained. elemental analysis
【表】
HPLCで分析した結果、純度は98〜99%であつ
た。[Table] As a result of HPLC analysis, the purity was 98-99%.
Claims (1)
素数1〜36の直鎖もしくは分岐鎖の、少なくとも
一つ以上の水素原子がフツ素原子で置換されたフ
ルオロアルキル基、Mは水素原子またはアルカリ
金属、アンモニウム、アルキルアミンもしくはア
ルカノールアミンの塩であることを示す。) で表される含フツ素リン酸エステル。[Claims] 1 General formula () (R' in the formula is a hydrogen atom or a methyl group, Rf is a linear or branched fluoroalkyl group having 1 to 36 carbon atoms in which at least one hydrogen atom is substituted with a fluorine atom, M is hydrogen A fluorine-containing phosphate ester represented by (indicates that it is a salt of an alkali metal, ammonium, alkylamine or alkanolamine).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61036988A JPS62195390A (en) | 1986-02-21 | 1986-02-21 | Fluorine containing phosphoric acid ester |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61036988A JPS62195390A (en) | 1986-02-21 | 1986-02-21 | Fluorine containing phosphoric acid ester |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62195390A JPS62195390A (en) | 1987-08-28 |
| JPH0327555B2 true JPH0327555B2 (en) | 1991-04-16 |
Family
ID=12485129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61036988A Granted JPS62195390A (en) | 1986-02-21 | 1986-02-21 | Fluorine containing phosphoric acid ester |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62195390A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846516A (en) * | 1992-06-03 | 1998-12-08 | Alliance Pharmaceutial Corp. | Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications |
-
1986
- 1986-02-21 JP JP61036988A patent/JPS62195390A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62195390A (en) | 1987-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2877958B2 (en) | Ethylenically unsaturated compounds | |
| US4736051A (en) | Process for the preparation of an alkali metal salt of a diester phosphoric acid | |
| JP3052923B2 (en) | Method for producing (meth) acrylate derivative | |
| GB2172889A (en) | Phosphoric esters | |
| JPH0327555B2 (en) | ||
| US4740609A (en) | Phosphoric esters and process for preparing same | |
| EP0242781B1 (en) | Phosphoric esters and process for preparing the same | |
| JPH0455433B2 (en) | ||
| US7202228B2 (en) | Hydrogelation agents | |
| JPH0327557B2 (en) | ||
| CN101928301B (en) | Method for synthesizing levofosfomycin dextrophenethylamine salt from dextrofosfomysin levophenethylamine salt | |
| JP3419030B2 (en) | Method for producing phosphorylcholine derivative | |
| JP7723413B2 (en) | Methods for producing zwitterionic compounds | |
| JPS61229888A (en) | Production of phosphoric acid ester | |
| JPS6215210A (en) | Novel polymer containing phosphate group and production thereof | |
| JP3171279B2 (en) | Method for producing alkylphosphocholine having 14 to 18 carbon atoms and method for purifying alkylphosphocholine | |
| CN111057100A (en) | Preparation method of phosphatidylglycerol monosodium salt containing two different side chains | |
| JPH0148914B2 (en) | ||
| JP2649343B2 (en) | Method for producing phosphate ester | |
| JP3526369B2 (en) | Fluoroalkyl group-containing phosphate triester and method for producing the same | |
| JPH0660185B2 (en) | Method for producing phosphate ester | |
| JPS63178842A (en) | Agent for forming liposome | |
| CN121248660A (en) | Synthesis method of oleoyl lysophosphatidylethanolamine | |
| JPS6215211A (en) | Water-soluble resin | |
| JPS63287545A (en) | Agent for forming liposome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |